Cipla gets USFDA nod for generic cancer drug
[ad_1] Cipla’s protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for injectable suspension 100 mg/vial | Photo Credit: DANISH SIDDIQUI
[ad_1] Cipla’s protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for injectable suspension 100 mg/vial | Photo Credit: DANISH SIDDIQUI